Thirupathi Gandla's Contact Details

Thirupathi Gandla's Company Details

VIVIMED LABS EUROPE LTD

HUDDERSFIELD, N/A, gb • 10 - 19 Employees
Chemical Manufacturing

Established in 1991 in Hyderabad, India, Vivimed Labs has metamorphosed from a domestic small, entrepreneurial family-operated business to a globally renowned supplier of niche molecules and formulations across Healthcare, Pharmaceuticals and Specialty Chemicals consumers in nearly 50 countries.Driven by our philosophy of using chemistry as a base to create ingredients which touch human life on a day to day basis, Vivimed Labs delivers world-class products across the various segments we serve.The active ingredients manufactured by us are the preferred ingredients in Home & Personal care segments such as hair, skin, oral care and anti-microbial preservatives, by leading global FMCG conglomerates. Our current product portfolio caters to over 75% of the ingredient market. We are also present in the Industrial care segments such as, photo chromic dyes and imaging chemicals. We will soon be expanding our operations into the fast-emerging and highly demanding sector of Printable Electronics and Organic Semiconductors.Vivimed's presence in Active Pharmaceutical Ingredients (API), Finished Dosage Formulation (FDF) and Retail Branded Formulation manufacturing, caters to the inner health of people. Within the FDF business, it provides contract manufacturing services and the manufacture of branded formulations.Within 25 years of our inception, we have established, 12 manufacturing facilities, 5 R&D centers (3 domestic and 2 overseas) and global support offices in India, China, Europe and USA. Our focus on quality and compliance reflects in everything we do – 4 of our manufacturing facilities are US- FDA approved and we have also gained PIC/S GMP approval for the supply of finished pharmaceutical formulations.The phenomenal growth scripted by Vivimed Labs is acknowledgments to our vision, strong transnational management team, and strategic investments. Our investments in innovations and differentiated research translate into a value-accretive product pipeline.